Skip to main content
logo
Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
149.97
-0.36 (-0.24%)
Aug 28, 2026, 4:00 PM EDT - Market closed

Palvella Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-61.7-41.72-17.4318.69-27.55
Stock-Based Compensation
12.416.40.830.60.43
Other Operating Activities
8.196.495.96-29.8510.66
Change in Accounts Receivable
0.390.39---
Change in Accounts Payable
2.221.262.24-2.251.98
Change in Other Net Operating Assets
2.312.17-2.43-0.9-0.36
Operating Cash Flow
-36.51-25.01-10.84-13.7-14.84
Operating Cash Flow Growth
-----

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Long-Term Debt Issued
--18.435-
Net Debt Issued (Repaid)
--18.435-
Issuance of Common Stock
232.580.7660-0.03
Other Financing Activities
-16.38-1.428.66--
Financing Cash Flow
216.2-0.6687.0959.57

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Foreign Exchange Rate Adjustments
0.150.050--
Net Cash Flow
117.37-25.6276.25-8.7-5.27

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Levered Free Cash Flow
-25.45-18.63-5.43-9.96-
Unlevered Free Cash Flow
-20.7-14.99-2.74-9.96-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22
Change in Working Capital
4.923.82-0.19-3.151.62
SEC Filings: 10-K · 10-Q